Bio-Rad Laboratories (BIO) Expected to Post Earnings of $0.90 Per Share

Analysts forecast that Bio-Rad Laboratories (NYSE:BIO) will report $0.90 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Bio-Rad Laboratories’ earnings. The lowest EPS estimate is $0.68 and the highest is $1.12. Bio-Rad Laboratories posted earnings per share of $0.41 in the same quarter last year, which indicates a positive year over year growth rate of 119.5%. The firm is expected to report its next quarterly earnings report after the market closes on Tuesday, May 8th.

According to Zacks, analysts expect that Bio-Rad Laboratories will report full-year earnings of $5.73 per share for the current year, with EPS estimates ranging from $5.50 to $5.96. For the next fiscal year, analysts anticipate that the business will report earnings of $7.40 per share, with EPS estimates ranging from $7.35 to $7.45. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Bio-Rad Laboratories.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.22. The business had revenue of $620.43 million for the quarter, compared to analysts’ expectations of $618.89 million. Bio-Rad Laboratories had a return on equity of 3.63% and a net margin of 5.31%.

Several research firms recently issued reports on BIO. ValuEngine upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Wells Fargo raised their target price on Bio-Rad Laboratories from $280.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, March 20th. Jefferies Group raised their target price on Bio-Rad Laboratories to $325.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. CL King cut Bio-Rad Laboratories from a “buy” rating to a “neutral” rating in a report on Friday, February 16th. Finally, Citigroup raised their target price on Bio-Rad Laboratories to $325.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Bio-Rad Laboratories currently has an average rating of “Buy” and a consensus target price of $297.20.

Bio-Rad Laboratories stock traded down $0.08 during mid-day trading on Wednesday, hitting $258.85. The stock had a trading volume of 111,360 shares, compared to its average volume of 159,516. The stock has a market cap of $7,793.15, a price-to-earnings ratio of 63.13, a P/E/G ratio of 3.04 and a beta of 0.94. Bio-Rad Laboratories has a 12 month low of $208.95 and a 12 month high of $279.59. The company has a quick ratio of 2.75, a current ratio of 3.93 and a debt-to-equity ratio of 0.15.

A number of institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. raised its position in shares of Bio-Rad Laboratories by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 30,855 shares of the medical research company’s stock worth $6,861,000 after purchasing an additional 5,823 shares during the period. Janus Henderson Group PLC raised its position in shares of Bio-Rad Laboratories by 8.4% during the third quarter. Janus Henderson Group PLC now owns 36,310 shares of the medical research company’s stock worth $8,069,000 after purchasing an additional 2,800 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Bio-Rad Laboratories during the third quarter worth about $626,000. California Public Employees Retirement System raised its position in shares of Bio-Rad Laboratories by 3.6% during the third quarter. California Public Employees Retirement System now owns 60,557 shares of the medical research company’s stock worth $13,457,000 after purchasing an additional 2,118 shares during the period. Finally, Winslow Asset Management Inc. raised its position in shares of Bio-Rad Laboratories by 4.1% during the fourth quarter. Winslow Asset Management Inc. now owns 28,042 shares of the medical research company’s stock worth $6,693,000 after purchasing an additional 1,112 shares during the period. Hedge funds and other institutional investors own 64.39% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://ledgergazette.com/2018/05/18/bio-rad-laboratories-bio-expected-to-post-earnings-of-0-90-per-share.html.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics.

Get a free copy of the Zacks research report on Bio-Rad Laboratories (BIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply